Clinical neuropsychology in perspective: Future challenges based on current developments;Neuropsicología clínica en perspectiva: Retos futuros basados en desarrollos presentes

Revista de Neurologia

Volumn 54, Issue 3, 2012, Pages 180-186

  Verdejo García, Antonio ^a   Tirapu Ustárroz, Javier ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Brain mind; Gene environment; Neurodevelopment; Neuroscience; Psychopathology; Reason emotion

Indexed keywords

NEUROPSYCHOLOGY; NEUROSCIENCE; REVIEW;

EID: 84856767440     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5403.2011499     Document Type: Review

References (49)

1. Bilder RM. Neuropsychology 3.0: evidence-based science and practice. J Int Neuropsychol Soc 2011; 17: 7-13.
2. Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment. New York: Oxford University Press; 2004.
3. Tirapu J, Maestú F, González-Márquez J, Ríos-Lago M, Ruiz MJ. Visión histórica y concepto de neuropsicología. In Tirapu J, Ríos-Lago M, Maestú F, eds. Manual de neuropsicología. Barcelona: Viguera; 2008. p. 1-32.
4. Pérez-García M, Puente A, Vilar-López R. Definición conceptual y profesional de neuropsicología clínica. In Pérez-García M, ed. Manual de neuropsicología clínica. Madrid: Pirámide; 2009. p. 19-29.
5. Tirapu-Ustárroz J. Para qué sirve el cerebro?: manual para principiantes. Bilbao: Desclée de Brouwer; 2008.
6. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-89.
7. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8: 828-34.
8. Hariri AR, Holmes A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn Sci 2006; 10: 182-91.
9. Ebstein RP. The molecular genetic architecture of human personality: beyond self-report questionnaires. Mol Psychiatry 2006; 11: 427-45.
10. Miller G. Epigenetics. A role for epigenetics in cognition. Science 2010; 329: 27.
11. Champagne FA, Curley JP. Epigenetic mechanisms mediating the long-term effects of maternal care on development. Neurosci Biobehav Rev 2009; 33: 593-600.
12. Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS, et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 2008; 13: 709-16.
13. Krueger F, Pardini M, Huey ED, Raymont V, Solomon J, Lipsky RH, et al. The role of the Met66 brain-derived neurotrophic factor allele in the recovery of executive functioning after combatrelated traumatic brain injury. J Neurosci 2011; 31: 598-606.
14. Damasio A. El error de Descartes: la emoción, la razón y el cerebro humano. Barcelona: Crítica; 1996.
15. Panksepp J. Affective neuroscience. Oxford: Oxford University Press; 1998.
16. Bechara A, Damasio H, Tranel D, Damasio AR. Deciding advantageously before knowing the advantageous strategy. Science 1997; 275: 1293-5.
17. Dunn BD, Galton HC, Morgan R, Evans D, Oliver C, Meyer M, et al. Listening to your heart. How interoception shapes emotion experience and intuitive decision making. Psychol Sci 2010; 21: 1835-44.
18. Alcaro A, Panksepp J. The SEEKING mind: primal neuroaffective substrates for appetitive incentive states and their pathological dynamics in addictions and depression. Neurosci Biobehav Rev 2011; 35: 1805-20.
19. Grace AA. Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotox Res 2010; 18: 367-76.
20. Aupperle RL, Melrose AJ, Stein MB, Paulus MP. Executive function and PTSD: disengaging from trauma. Neuropharmacology 2011; Feb 22. [Epub ahead of print].
21. Banich MT, Mackiewicz KL, Depue BE, Whitmer AJ, Miller GA, Heller W. Cognitive control mechanisms, emotion and memory: a neural perspective with implications for psychopathology. Neurosci Biobehav Rev 2009; 33: 613-30.
22. Bora E, Yücel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr Bull 2010; 36: 36-42.
23. Blair RJ. The amygdala and ventromedial prefrontal cortex: functional contributions and dysfunction in psychopathy. Philos Trans R Soc Lond B Biol Sci 2008; 12: 2557-65.
24. Domes G, Schulze L, Herpertz SC. Emotion recognition in borderline personality disorder: a review of the literature. J Pers Dis 2009; 23: 6-19.
25. Haaland VO, Esperaas L, Landrø NI. Selective deficit in executive functioning among patients with borderline personality disorder. Psychol Med 2009; 39: 1733-43.
26. Helzer JE, Bucholz KK, Gossop M. A dimensional option for the diagnosis of substance dependence in DSM-V. Int J Methods Psychiatr Res 2007; 16 (Suppl 1): S24-S33.
27. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60: 889-96.
28. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.
29. Menzies L, Achard S, Chamberlain SR, Fineberg N, Chen CH, Del Campo N, et al. Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain 2007; 130: 3223-36.
30. Verdejo-García A, Lawrence AJ, Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 2008; 32: 777-810.
31. Tenconi E, Santonastaso P, Degortes D, Bosello R, Titton F, Mapelli D, et al. Set-shifting abilities, central coherence, and handedness in anorexia nervosa patients, their unaffected siblings and healthy controls: exploring putative endophenotypes. World J Biol Psychiatry 2010; 11: 813-23.
32. Blair RJ, Colledge E, Mitchell DG. Somatic markers and response reversal: is there orbitofrontal cortex dysfunction in boys with psychopathic tendencies? J Abnorm Child Psychol 2006; 29: 499-511.
33. Davey CG, Yücel M, Allen NB. The emergence of depression in adolescence: development of the prefrontal cortex and the representation of reward. Neurosci Biobehav Rev 2008; 32: 1-19.
34. Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008: 9: 947-57.
35. Whittle S, Yücel M, Fornito A, Barrett A, Wood SJ, Lubman DI, et al. Neuroanatomical correlates of temperament in early adolescents. J Am Acad Child Adolesc Psychiatry 2008; 47: 682-93.
36. Waber DP, De Moor C, Forbes PW, Almli CR, Botteron KN, Leonard G, et al. The NIH MRI study of normal brain development: performance of a population based sample of healthy children aged 6 to 18 years on a neuropsychological battery. J Int Neuropsychol Soc 2007; 13: 729-46.
37. Whittle S, Yücel M, Yap MB, Allen NB. Sex differences in the neural correlates of emotion: Evidence from neuroimaging. Biol Psychol 2011; 87: 319-33.
38. Lenroot RK, Giedd JN. Sex differences in the adolescent brain. Brain Cogn 2010; 72: 46-55.
39. Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, et al. Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 2004; 5: 421-5.
40. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008; 33: 1477-502.
41. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010; 67: 692-4.
42. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ, et al. Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology 2009; 207: 133-42.
43. Cappell J, Herrmann N, Cornish S, Lanctôt KL. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. CNS Drugs 2010; 24: 909-27.
44. Barch DM. Pharmacological strategies for enhancing cognition in schizophrenia. Curr Top Behav Neurosci 2010; 4: 43-96.
45. Liepert J. Pharmacotherapy in restorative neurology. Curr Opin Neurol 2008; 21: 639-43.
46. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 2010; 105: 38-48.
47. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, et al. Towards responsible use of cognitiveenhancing drugs by the healthy. Nature 2008; 456: 702-5.
48. Makrides M, Gibson RA, McPhee AJ, Yelland L, Quinlivan J, Ryan P. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA 2010; 304: 1675-83.
49. Szajewska H, Ruszczynski M, Chmielewska A. Effects of iron supplementation in nonanemic pregnant women, infants, and young children on the mental performance and psychomotor development of children: a systematic review of randomized controlled trials. Am J Clin Nutrition 2010; 91: 1684-90.